No Data
No Data
BeyondSpring (NASDAQ:BYSI) Shareholders Have Earned a 141% Return Over the Last Year
Express News | BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics
Express News | BeyondSpring Reports FY23 Loss Per Share Of $(0.54) Vs. $(0.85) Last Year
Press Release: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.
BeyondSpring Files 2023 Annual Report on Form 20-F
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer
Express News | Beyondspring Provides Business Update and Reports Year End 2023 Financial Results
No Data